HYBN: Hybridon, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HYBN: Hybridon, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: a.m. fisher	12/13/2001 9:54:49 AM
	Read Replies (1) of 28

ISIS Pharm (ISIP) 19.15: Co and Amgen (AMGN) have entered into a 3-yr collaboration to discover new antisense drugs. If drugs from the collaboration are successful, Isis will receive milestone payments upon key clinical and commercial achievements, as well as royalties on sales. The therapeutic area of research and financial terms of the transaction were not disclosed. Remember HYBN's deal with ISIS ...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next